

## FITC anti-human IgD Antibody

|                          |   |
|--------------------------|---|
| <b>Catalog# / Size</b>   | 348205 / 25 tests<br>348206 / 100 tests   |
| <b>Clone</b>             | IA6-2   |
| <b>Regulatory Status</b> | RUO   |
| <b>Other Names</b>       | Ig delta chain C region   |
| <b>Isotype</b>           | Mouse IgG2a, κ  |
| <b>Description</b>       | IgD, a member of the immunoglobulin (Ig) family, is expressed in naïve B cells. It has 3 Ig-like domains and exists in a transmembrane and a soluble form. In general, IgD is not secreted and usually its expression is lost after the Ig isotype switch. After antigen binding, IgD signals through the CD79a/CD79b (Igα/Igβ) heterodimer, resulting in the activation of the B cell. |

### Product Details

---

|   |   |
|---|---|
| <b>Verified Reactivity</b>  | Human   |
| <b>Antibody Type</b>  | Monoclonal  |
| <b>Host Species</b>   | Mouse   |
| <b>Immunogen</b>  | Human IgD   |
| <b>Formulation</b>  | Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)   |
| <b>Preparation</b>  | The antibody was purified by affinity chromatography, and conjugated with FITC under optimal conditions.  |
| <b>Concentration</b>  | Lot-specific (to obtain lot-specific concentration, please enter the lot number in our <a href="#">Concentration and Expiration Lookup</a> or <a href="#">Certificate of Analysis</a> online tools.)  |
| <b>Storage &amp; Handling</b>   | The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>   |
| <b>Application</b>  | <a href="#">FC - Quality tested</a>   |
| <b>Recommended Usage</b>  | Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.  |
| <b>Excitation Laser</b>   | Blue Laser (488 nm)   |
| <b>Application Notes</b>  | Additional reported applications (for the relevant formats) include: immunohistochemical staining of paraformaldehyde fixed frozen sections <sup>4</sup> and spatial biology (IBEX) <sup>5,6</sup> .  |
| <b>Application References</b><br>(PubMed link indicates BioLegend citation) | <ol style="list-style-type: none"> <li>Chen K, <i>et al.</i> 2009. <i>Nat. Immunol.</i> 10:889.</li> <li>Lee CH, <i>et al.</i> 2005. <i>J. Exp. Med.</i> 203:63.</li> <li>Sutter JA, <i>et al.</i> 2008. <i>Clin. Immunol.</i> 126:282.</li> <li>Li H and Pauza CD. 2015. <i>Eur. J. Immunol.</i> 45:298. (IHC)</li> <li>Radtke AJ, <i>et al.</i> 2020. <i>Proc Natl Acad Sci USA.</i> 117:33455-33465. (SB) <a href="#">PubMed</a></li> <li>Radtke AJ, <i>et al.</i> 2022. <i>Nat Protoc.</i> 17:378-401. (SB) <a href="#">PubMed</a></li> </ol>   |
| <b>Product Citations</b>  | <ol style="list-style-type: none"> <li>Xu Y, <i>et al.</i> 2022. <i>Nat Commun.</i> 13:980. <a href="#">PubMed</a></li> <li>Nakano M, <i>et al.</i> 2021. <i>Front Immunol.</i> 12:713225. <a href="#">PubMed</a></li> <li>Li H, <i>et al.</i> 2016. <i>J Immunol.</i> 196: 4064 - 4074. <a href="#">PubMed</a></li> <li>Mukhamedova M, <i>et al.</i> 2021. <i>Immunity.</i> 54(4):769-780.e6. <a href="#">PubMed</a></li> <li>SoRelle ED, <i>et al.</i> 2022. <i>Cell Rep.</i> 40:111286. <a href="#">PubMed</a></li> <li>Munteanu AN, <i>et al.</i> 2019. <i>Exp Ther Med.</i> 18:1693. <a href="#">PubMed</a></li> <li>Palamides P, <i>et al.</i> 2016. <i>Dis Model Mech.</i> 9: 985 - 997. <a href="#">PubMed</a></li> <li>van der Burg M, <i>et al.</i> 2019. <i>Front Immunol.</i> 10:246. <a href="#">PubMed</a></li> <li>Zost SJ, <i>et al.</i> 2020. <i>Nat Med.</i> 26:1422. <a href="#">PubMed</a></li> </ol> |

10. Wu X, *et al.* 2016. *Sci Rep.* 6:36378. [PubMed](#)
11. van Heerden D, *et al.* 2021. *Int J Mol Sci.* 22:.. [PubMed](#)
12. Zost SJ, *et al.* 2020. *bioRxiv.* . [PubMed](#)
13. Pallikkuth S, *et al.* 2020. *eLife.* 9:e51889.. [PubMed](#)
14. Tong P, *et al.* 2021. *Cell.* .: [PubMed](#)
15. Benhammou JN, *et al.* 2020. *Dig Dis Sci.* 66:2394. [PubMed](#)
16. Klymenko T, *et al.* 2018. *Leukemia.* 19:E499. [PubMed](#)
17. Jiang R, *et al.* 2020. *JCI Insight.* 5:.. [PubMed](#)
18. Fu Y, *et al.* 2021. *Cell Reports.* 36(2):109344. [PubMed](#)
19. van der Velden V, *et al.* 2017. *J Immunol Methods.* 10.1016/j.jim.2017.03.011. [PubMed](#)
20. Heiden M, *et al.* 2016. *Sci Rep.* 6: 26892. [PubMed](#)
21. Rother M, *et al.* 2016. *J Immunol.* 197: 441 - 448. [PubMed](#)
22. Martin GE, *et al.* 2018. *Front Immunol.* 1.019444444. [PubMed](#)
23. van Dongen JMM, *et al.* 2019. *Front Immunol.* 10:1271. [PubMed](#)

**RRID** AB\_10613638 (BioLegend Cat. No. 348205)  
 AB\_10612567 (BioLegend Cat. No. 348206)

## Antigen Details

|                           |   |
|---------------------------|---|
| <b>Structure</b>          | Exists in a transmembranal and a soluble form   |
| <b>Distribution</b>       | Naïve B cells   |
| <b>Function</b>           | Antigen binding, B cell activation  |
| <b>Interaction</b>        | The CD79a/CD79b heterodimer   |
| <b>Cell Type</b>          | B cells   |
| <b>Biology Area</b>       | Immunology  |
| <b>Antigen References</b> | <ol style="list-style-type: none"> <li>1. Geisberger R, <i>et al.</i> 2006. <i>Immunology</i> 118:429.</li> <li>2. Weller S, <i>et al.</i> 2005. <i>Eur. J. Immunol.</i> 35:2789.</li> <li>3. Brandtzaeg P and Johansen FE. 2005. <i>Immunol. Rev.</i> 206:32.</li> </ol> |
| <b>Gene ID</b>            | <a href="#">3495</a>  |


## Related Protocols


[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats

Alexa Fluor® 647 anti-human IgD, PerCP anti-human IgD, Brilliant Violet 605™ anti-human IgD, Alexa Fluor® 700 anti-human IgD, Purified anti-human IgD, PE anti-human IgD, Biotin anti-human IgD, FITC anti-human IgD, PerCP/Cyanine5.5 anti-human IgD, PE/Cyanine7 anti-human IgD, Alexa Fluor® 488 anti-human IgD, APC/Cyanine7 anti-human IgD, Brilliant Violet 510™ anti-human IgD, APC anti-human IgD, Pacific Blue™ anti-human IgD, Brilliant Violet 421™ anti-human IgD, Purified anti-human IgD (Maxpar® Ready), PE/Dazzle™ 594 anti-human IgD, APC/Fire™ 750 anti-human IgD, Brilliant Violet 785™ anti-human IgD, TotalSeq™-A0384 anti-human IgD, TotalSeq™-C0384 anti-human IgD, TotalSeq™-B0384 anti-human IgD, PE/Cyanine5 anti-human IgD, TotalSeq™-D0384 anti-human IgD

## Product Data





For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587